Becton Dickinson & Co. closed 20.98% short of its 52-week high of $251.99, which the company reached on February 3rd.

The solution enables the use of BD's Synapsis informatics with BD Phoenix M50 automated microbiology and rapid identification and AST on the BDXpert system.

Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major ...

This was the stock's third consecutive day of losses.

Barclays lowered the firm’s price target on Becton Dickinson (BDX) to $261 from $279 and keeps an Overweight rating on the shares. The firm ...

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The firm is not ...

Becton, Dickinson and Co. also reported slightly higher pay for the device developer and manufacturer's median worker in ...

BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, May 1, 2025 to discuss the ...

In addition to job gains, local leaders see Arizona emerging as one of the nation’s most dynamic hubs for bioscience ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Centesis Catheters Market Worth ...

Clinical Diagnostic Market Growth BURLINGAME, CA, UNITED STATES, April 2, 2025 /EINPresswire / -- The Latest study titled Clinical Diagnostic ...

Recent high-profile financial activities involve Andreessen Horowitz's potential investment in TikTok, EU fines for a vehicle ...